Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 22,689 shares of Zymeworks stock in a transaction that occurred on Monday, March 24th. The shares were purchased at an average cost of $13.08 per share, with a total value of $296,772.12. Following the transaction, the director now directly owns 17,157,802 shares of the company's stock, valued at $224,424,050.16. This represents a 0.13 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Friday, March 21st, Ecor1 Capital, Llc acquired 31,033 shares of Zymeworks stock. The stock was acquired at an average cost of $12.78 per share, for a total transaction of $396,601.74.
- On Wednesday, March 19th, Ecor1 Capital, Llc purchased 58,306 shares of Zymeworks stock. The stock was acquired at an average price of $12.64 per share, with a total value of $736,987.84.
- On Monday, March 17th, Ecor1 Capital, Llc acquired 56,277 shares of Zymeworks stock. The shares were acquired at an average cost of $12.23 per share, for a total transaction of $688,267.71.
- On Thursday, March 13th, Ecor1 Capital, Llc bought 468,356 shares of Zymeworks stock. The stock was acquired at an average cost of $12.48 per share, with a total value of $5,845,082.88.
- On Tuesday, March 11th, Ecor1 Capital, Llc purchased 320,690 shares of Zymeworks stock. The shares were bought at an average cost of $11.49 per share, for a total transaction of $3,684,728.10.
- On Friday, January 17th, Ecor1 Capital, Llc acquired 19,748 shares of Zymeworks stock. The shares were bought at an average price of $13.87 per share, for a total transaction of $273,904.76.
- On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The stock was bought at an average cost of $14.01 per share, with a total value of $546,796.29.
- On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The shares were purchased at an average cost of $13.39 per share, for a total transaction of $992,533.75.
- On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The shares were purchased at an average price of $13.13 per share, with a total value of $2,679,806.74.
- On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The stock was purchased at an average cost of $14.07 per share, for a total transaction of $295,765.47.
Zymeworks Price Performance
Shares of ZYME stock opened at $13.05 on Tuesday. Zymeworks Inc. has a one year low of $7.97 and a one year high of $17.70. The company's fifty day moving average price is $13.71 and its 200-day moving average price is $13.72. The company has a market capitalization of $907.98 million, a price-to-earnings ratio of -8.70 and a beta of 1.13.
Institutional Investors Weigh In On Zymeworks
Institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC boosted its stake in shares of Zymeworks by 781.5% in the fourth quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock worth $25,000 after acquiring an additional 1,524 shares during the period. AlphaQuest LLC boosted its stake in Zymeworks by 480.2% in the 4th quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock worth $41,000 after purchasing an additional 2,324 shares during the period. FMR LLC grew its holdings in Zymeworks by 84.2% during the 3rd quarter. FMR LLC now owns 3,336 shares of the company's stock valued at $42,000 after buying an additional 1,525 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in shares of Zymeworks during the fourth quarter valued at approximately $108,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Zymeworks by 343.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,704 shares of the company's stock worth $142,000 after buying an additional 7,518 shares in the last quarter. 92.89% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Several research firms have recently commented on ZYME. Lifesci Capital began coverage on shares of Zymeworks in a research report on Tuesday, March 11th. They set an "outperform" rating and a $30.00 price target for the company. Citigroup increased their price target on shares of Zymeworks from $18.00 to $19.00 and gave the stock a "buy" rating in a research report on Friday, March 7th. Wells Fargo & Company lifted their price target on shares of Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research note on Thursday, December 19th. JPMorgan Chase & Co. upgraded Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 price objective for the company in a research note on Monday, December 16th. Finally, HC Wainwright lifted their target price on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Zymeworks currently has an average rating of "Moderate Buy" and a consensus target price of $21.00.
Read Our Latest Report on ZYME
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
